Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)

Summary

To evaluate the safety and tolerability of ZYN002 administered as a transdermal gel formulation, for up to 38 weeks, in participants ages 4 to \<18 years, in the treatment of 22q.11.2 Deletion syndrome (22qDS).

Timeline

Start

2020-02-19

Primary completion

2022-11-09

Completion

2022-11-09

Publications

• Heussler H, Cohen J, Buchanan CB, Albers DS, Bzdek KG. Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031). J Neurodev Disord. 2026 Mar 26;18(1):22. doi: 10.1186/s11689-026-09687-z.

Drugs

Indications